

03 · 2023



## Nachrichten und Mitteilungen

APV NEWS

International Association for Pharmaceutical Technology  
Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V.  
Gemeinnütziger wissenschaftlicher Verein



2024

**14<sup>th</sup> World Meeting on Pharmaceutics,  
Biopharmaceutics and Pharmaceutical Technology**

**Vienna**, Austria

18 - 21 March 2024

**PBP**  
**WORLD MEETING**  
in combination with  
**R**esearch**P**harm®  
*International Exhibition for R&D*



[www.worldmeeting.org](http://www.worldmeeting.org)



## Lokale Gruppen

**Donnerstag, 20. Juli 2023**

**Lokale APV-Gruppe Rhein-Neckar** ab 19:00 Uhr. Der Veranstaltungsort wird noch bekanntgegeben.

Weitere Informationen und Angaben zu den nächsten Terminen erhalten Sie bei Dr. Viktoria Riedel (viktoria.riedel@schwabe.de).



**Dienstag, 25. Juli 2023**

**Lokale APV-Gruppe Rhein-Main** ab 19:30 Uhr. Der Veranstaltungsort wird noch bekanntgegeben.

Weitere Informationen und Angaben zu dem Veranstaltungsort sowie den nächsten Terminen erhalten Sie bei Cathrin Pauly (pauly@aspiras.de).



**Dienstag, 19. September 2023**

**Lokale APV-Gruppe Berlin** ab 19:00 Uhr bei der PDA Europe (Am Borsigturm 60, 13507 Berlin).

Weitere Informationen und Angaben zu den nächsten Terminen erhalten Sie bei Dr. Andreas Sachse (andreas.sachse@cpl-sachse.de).



**Lokale APV-Gruppe Ulm/Biberach/Ravensburg/Bodensee**

Weitere Informationen und Angaben zu den nächsten Terminen erhalten Sie bei Dr. Martin Müller (martin.mueller@vetter-pharma.com).



**Lokale APV-Gruppe Basel**

Weitere Informationen und Angaben zu den nächsten Terminen erhalten Sie bei Dr. Lars Restetzki (lars.restetzki@roche.com).



**Lokale APV-Gruppe Westfalen**

Weitere Informationen und Angaben zu den nächsten Terminen erhalten Sie bei Dr. Johanna Anlahr (johanna.anlahr@bayer.com).



**Lokale APV-Gruppe Nordrhein**

Weitere Informationen und Angaben zu den nächsten Terminen erhalten Sie bei Klaus Wening (klaus.wening@grunenthal.com).



**Lokale APV-Gruppe Mecklenburg-Vorpommern**

Weitere Informationen und Angaben zu den nächsten Terminen erhalten Sie bei Katharina Tietz (katharina.tietz@uni-greifswald.de).



**Lokale APV-Gruppe Oberbayern**

Weitere Informationen und Angaben zu den nächsten Terminen erhalten Sie bei Dr. (USA) Julia Schulze-Nahrup (jsn@pharmoveo.de).



# What's hot in European Journal of Pharmaceutics and Biopharmaceutics?

Elena Richert, Ludwig-Maximilians-Universität, D-München

## Air-liquid interface (ALI) impact on different respiratory cell cultures

*Soraia Silva, Joana Bicker, Amílcar Falcão, Ana Fortuna*

The intranasal route has been receiving greater attention from the scientific community not only for systemic drug delivery but also for the treatment of pulmonary and neurological diseases. Along with it, drug transport and permeability studies across the nasal mucosa have exponentially increased. Nevertheless, the translation of data from *in vitro* cell lines to *in vivo* studies is not always reliable, due to the difficulty in generating an *in vitro* model that resembles respiratory human physiology. Among all currently available methodologies, the air-liquid interface (ALI) method is advantageous to promote cell differentiation and optimize the morphological and histological characteristics of airway epithelium cells. Cells grown under ALI conditions, in alternative to submerged conditions, appear to provide relevant input for inhalation and pulmonary toxicology and complement *in vivo* experiments. Different methodologies and a variety of materials have been used to induce ALI conditions in primary cells and numerous cell lines. Until this day, with only exploratory results, no consensus has been reached regarding the validation of the ALI method, hampering data comparison. The present review describes the most adequate cell models of airway epithelium and how these models are differently affected by ALI conditions. It includes the evaluation of cellular features before and after ALI, and the application of the method in primary cell cultures, commercial 3D primary cells, cell lines and stem-cell derived models. A variety of these models have been recently applied for pharmacological studies against severe acute respiratory syndrome–coronavirus(-2) SARS-CoV(-2), namely primary cultures with alveolar type II epithelium cells and organotypic 3D models. The herein compiled data suggest that ALI conditions must be optimized bearing in mind the type of cells (nasal, bronchial, alveolar), their origin and the objective of the study.

## Part II: Matrix based scaffold lyophilization facilitates processing as a prerequisite for an innovative packaging system

*Daniel Kullmann, Carmen Lema Martinez, Jörg Lümkemann, Jörg Huwyler*

On large manufacturing lines, the fill finish process of drugs is generally accomplished by filling vials and syringes with their respective deliverable doses. Glass as a final container provides excellent protection of the drug product because of its chemical inertia, gas

impermeability and relative robustness. However, due to potential needle stitch issues, diluent mix ups, or the required use of complex closed system transfer devices, lyophilizate vials present a significant challenge for healthcare professionals during the correct preparation of intravenous (IV) infusions. A more suitable container could potentially minimize such shortfalls during the preparation of IV infusions. Our investigations aimed at assessing if a novel medication system, consisting of an infusion bag separated into individual dry product and liquid diluent chambers, could facilitate the storage of a lyophilized product equivalently to the current standard, a vial. By incorporating an intermediate process container into two different dual chamber bags (DCB), the stability of a model monoclonal antibody formulation (mAb) was studied. The DCBs were evaluated over a 24-week period against their liquid and lyophilized dosage form equivalents in glass vials. Their stability was assessed through investigations into protein stability, residual moisture uptake of the dry products and permeability of the foil and film materials. It could be demonstrated that the stability of the incorporated drug is highly dependent on the container configuration. Ultimately it could be shown that the storage of lyophilizates is equally possible in DCBs as it is in vials, while being stored next to the diluent within the administration device.

## Application of biorelevant *in vitro* assays for the assessment and optimization of ASD-based formulations for pediatric patients

*Janis Niessen, Álvaro López Mármol, Ruba Ismail, Julia T. Schiele, Karola Rau, Andrea Wahl, Kerstin Sauer, Oliver Heinzerling, Jörg Breitkreutz, Mirko Koziolek*

Amorphous solid dispersions (ASD) have been a successful formulation strategy to overcome the poor aqueous solubility of many novel drugs, but the development of pediatric formulations presents a special challenge due to variable gastrointestinal conditions in children. It was the aim of this work to design and apply a staged biopharmaceutical test protocol for the *in vitro* assessment of ASD-based pediatric formulations. Ritonavir was used as a model drug with poor aqueous solubility. Based on the commercial ASD powder formulation, a mini-tablet and a conventional tablet formulation were prepared. Drug release from the three formulations was studied in different biorelevant *in vitro* assays (i.e. MicroDiss, two-stage, transfer model, tiny-TIM) to consider different aspects of human GI physiology. Data from the two-stage and transfer model tests indicated that by controlled disintegration and dissolution excessive primary precipitation can be prevented. However, this advantage

of the mini-tablet and tablet formulation did not translate into better performance in tiny-TIM. Here, the in vitro bioaccessibility was comparable for all three formulations. In the future, the staged biopharmaceutical action plan established herein will support the development of ASD-based pediatric formulations by improving the mechanistic understanding so that formulations are developed for which drug release is robust against variable physiological conditions.

### **Therapeutic deep eutectic solvents: A comprehensive review of their thermodynamics, microstructure and drug delivery applications**

*Magdy M. Abdelquader a b, Shu Li a, Gavin P. Andrews a, David S. Jones*

Deep eutectic solvents (DES) are multicomponent liquids that are usually formed by coupling a hydrogen bond donor and acceptor leading to strong non-covalent (NC) intermolecular networking and profound depression in the melting point of the system. Pharmaceutically, this phenomenon has been exploited to improve drugs' physicochemical properties, with an established DES therapeutic subcategory, therapeutic deep eutectic solvents (THEDES). THEDES preparation is usually via straightforward synthetic processes with little involvement of sophisticated techniques, which, in addition to its thermodynamic stability, make these multi-component molecular adducts a very attractive alternative for drug enabling purposes. Other NC bonded binary systems (e.g., co-crystals and ionic liquids) are utilized in the pharmaceutical field for enhancing drug's behaviours. However, a clear distinction between these systems and THEDES is scarcely discussed in the current literature. Accordingly, this review provides a structure-based categorization for DES formers, a discussion of its thermodynamic properties and phase behaviour, and it clarifies the physicochemical and microstructure boundaries between DES and other NC systems. Additionally, a summary of its preparation techniques and their experimental conditions preparation is supplied. Instrumental analysis techniques can be used to characterize and differentiate DES from other NC mixtures, hence this review draws a road map to for this purpose. Since this work mainly focuses on pharmaceutical applications of DES, all types of THEDES including the highly discussed types (conventional, drugs dissolved in DES and polymer based) in addition to the less discussed categories are covered. Finally, the regulatory status of THEDES was investigated despite the current unclear situation.

### **Impressum:**

#### **Redaktion**

Prof. Jörg Breitkreutz (Präsident der APV)  
Dr. Martin Bornhöft (Leiter der Geschäftsstelle der APV)

#### **Vorstand der APV**

Prof. Dr. Johannes Bartholomäus · Dr. Kathrin Bartscher · Dr. Karoline Bechtold-Peters ·  
Prof. Dr. Jörg Breitkreutz · Prof. Dr. Sandra Klein ·  
Dr. Martin Lück · Dr. Florian Unger · Dr. Alena Wieber

#### **Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e. V. (APV)**

Kurfürstenstr. 59 · 55118 Mainz · Germany  
Telefon +49 6131 9769-0  
Telefax +49 6131 9769-69  
email apv@apv-mainz.de  
web www.apv-mainz.de

#### **Verlag**

ECV · Editio Cantor Verlag für Medizin und Naturwissenschaften GmbH  
Baendelstockweg 20 · 88326 Aulendorf · Germany  
Telefon +49 7525 940-0  
Telefax +49 7525 940-180  
email info@ecv.de  
web www.ecv.de

Alle Rechte bei APV e.V. · All rights reserved · Printed in Germany · Jede Form des Nachdrucks verboten

#### **Druck**

Holzmann Druck GmbH & Co. KG  
Gewerbestr. 2 · 86825 Bad Wörishofen · Germany

#### **Satz**

Anna-Maria Pötzl · APV e.V.

## Leasing auch für andere Investitionsgüter

### Leasing und Finanzierung von Investitionsgütern zu günstigen Konditionen:

- ✓ schont das Eigenkapital
- ✓ verbessert das Rating
- ✓ schafft Liquidität
- ✓ ermöglicht den Einsatz neuester Technologie
- ✓ ist bilanzneutral
- ✓ auch „sale and lease back“ möglich
- ✓ erhöht die Eigenkapitalquote

### Sehr interessant auch für Nutzer von Maschinen für die Pharmaindustrie:

- ✓ niedrige Leasingraten statt hoher Kaufpreise
- ✓ kein Bonitäts-/Ausfallrisiko für Hersteller/Händler
- ✓ Erweiterung der Dienstleistungspalette vom Verkäufer zum
- ✓ Finanzierung von Neu- und Gebrauchtmaschinen
- ✓ Full-Service-Anbieter
- ✓ Abdeckung der kompletten Produktpalette
- ✓ erhöhte Kompetenz als „all in one“-Anbieter

Unser Kooperationspartner bietet Leasing von Neu- und Gebrauchtfahrzeugen zu Sonderkonditionen an. Alle Marken und Modelle sind lieferbar. Die nachfolgende Tabelle gibt nur wenige aktuelle Beispiele möglicher Modelle und Marken wieder.

NEU: Vorführwagen (VfW) aus dem Leasing-Pool und Dienst-/Werksfahrzeuge (DW) zu attraktiven Konditionen erhältlich.

Alle Preise in Euro zuzüglich gesetzlicher Mehrwertsteuer. Beschaffung durch die Leasing-Gesellschaft. 24/36/48/60 Monate Laufzeit (LZ), ohne Anzahlung, Laufleistung 10.000 km pro Jahr, gewerbliches Leasing, Angebote freibleibend. Der Nachlass auf den Listenpreis ist in die ermäßigte Rate einkalkuliert. Der jeweilige BAFA-Anteil ist bei den Plug-In-Hybrid Fahrzeugen und den reinen Elektrofahrzeugen (ZOE) bereits wie eine Anzahlung berücksichtigt. (\* = Service inklusive).

Anfragen bitte an [apv@apv-mainz.de](mailto:apv@apv-mainz.de), das Leasing-Unternehmen wird sich dann mit Ihnen in Verbindung setzen.

### Kfz-Leasing

Hersteller/Typ	LZ	Listenpreis	mtl. Rate
BMW X1 sDrive18d 110kW/150PS inkl. Steptronic, xLine, Premiumpaket, Metallic, Klimaautomatik, Parking Assistant, Sitzheizung Fahrer/Beifahrer, 19" LMR V-Speiche 867 Bicolor etc.	48	44.336,00 €	539,00 €
BMW 318d Touring 110kW/150PS Automatik inkl. Klimaautomatik, Widescreen, Live Cockpit Plus, Diving+Parking Assistant, Metallic, Sportsitze und Sitzheizung vorn, 17" LMR etc.	48	45.941,00 €	569,00 €
CUPRA Formentor 1.5 TSI 110kW/150PS 6-Gang inkl. Automatische Distanzregelung, Spurhalteassistent, Einparkhilfe hinten, 3-Zonen-Climatronic, Voll-LED Scheinwerfer, 18" LMR etc.	24	29.857,00 €	199,00 €
CUPRA Leon Sportstourer 2.0 TSI 180kW/245PS DSG inkl. 3-Zonen-Climatronic, Front Assist, Spurhalteassistent, Tempomat, Lenkrad beheizbar, Ultraschall-Einparkhilfe hinten, 18" LMR etc.	24	33.357,00 €	219,00 €
DACIA Sandero Stepway Expression TCe 90 66kW/90PS inkl. Multimediasystem mit 8" Touchscreen, Klimaanlage, Sicherheits-Paket, Tempopilot, Einparkhilfe hinten, DACIA Full Service! etc.	48	14.752,00 €	199,00 €
Land Rover Range Rover Evoque P200 aut. R-Dynamic SE AWD 147kW/200PS Automatik inkl. Navi, Meridian Soundsystem, Einparkhilfe mit Rückfahrkamera, Fahrersitz/Memory, Totwinkelwarner etc.	48	53.550,00 €	559,00 €
Lexus UX 250h Style Edition 135kW/185PS Automatik inkl. Metallic-Lackierung, Navigationssystem, PDC hinten/Kamera, LED Scheinwerfer, Tempomat, 18" Alufelgen, Wartungsservice etc.	48	38.655,00 €	439,00 €
MINI Cooper 5-Türer 100kW/136PS inkl. Automatik, Premium Extra, Midnight Black Metallic, Classic Trim, Navi, Klimaautomatik, Sitzheizung Fahrer/Beifahrer, PDC hinten/Kamera, 16" LMR etc.	48	28.277,00 €	339,00 €
Renault Master Kastenwagen Komfort L3H2 3,5t ENERGY Blue dCi 150 inkl. Navi Media Nav Evolution DAB+, PDC hinten, Rückfahrkamera, Toter-Winkel-Warner, Ganzjahresreifen, Ersatzrad etc.	60	43.815,00 €	419,00 €
Seat Arona FR 1.0 TSI 81kW/110PS 6-Gang inkl. Vorteilspaket FR Pro, Navigationssystem, Climatronic, Parklenkassistent mit Einparkhilfe v+h Rückfahrkamera, Wireless Charger, 17" LMR etc.	24	23.945,00 €	159,00 €
Toyota Yaris 1.5-I-VVT-i Hybrid CVT Team Deutschland 85kW/116PS inkl. Klimaautomatik, Audioanlage, Einparkassistent/-hilfe hinten, Kamera, Tempomat, 16" Alufelgen, Wartungsservice etc.	36	21.890,00 €	279,00 €
Toyota C-HR 1.8-I-VVTi Hybrid Flow 90kW/122PS Automatik inkl. 2-Zonen-Klimaautomatik, Spurassistent, PDC hinten/Kamera, LED Scheinwerfer, Audioanlage, 17" LMF, Wartungsservice etc.	48	27.723,00 €	349,00 €
VW T-Cross Style 1,0 I TSI OPF 81kW/110PS inkl. 2-Zonen-Klimaautomatik, Einparkhilfe vorn und hinten, Sitzheizung vorne, Tempomat, LED-Scheinwerfer, 17" LMR Chesterfield etc.	48	24.370,00 €	239,00 €